Meningococcal group a, c, w-135 and y conjugate vaccine

On 1 register2 medicines2 companies

Classification

Anatomical main groupJAnti-infectives for systemic use
Therapeutic subgroupJ07
Pharmacological subgroupJ07A
Chemical subgroupJ07AHMeningococcal vaccines
Chemical substanceJ07AH08Meningococcus a, c, y, w-135, tetravalent purified polysaccharides antigen conjugated

Each register with its number of medicines and a few of them.

Every register, a page at a time. Strengths and packs are on each medicine’s page.

9 results

Medicine	Register	Strength	Form	Status	Holder
Menveo	European Union			Authorised	GSK Vaccines S.r.l.
MenQuadfi	European Union			Authorised	Sanofi Winthrop Industrie
MenveoCombination	United States	0.5ML	Injection	Marketed	GlaxoSmithKline Biologicals
MenveoCombination	United States	0.5ML	Injection	Marketed	GlaxoSmithKline Biologicals
MenactraCombination	United States	48UG/.5ML	For Injection	Marketed	Sanofi Vaccines US Inc.
Nimenrix	European Union			Authorised	Pfizer Europe MA EEIG
MenomuneCombination	United States	50UG/.5ML	For Injection	Withdrawn	Sanofi Vaccines US Inc.
Menveo Powder and Solution for Solution for InjectionCombination	Singapore	10 microgram conjugated to 16.7-33.3 microgram + 5 microgram conjudated to 7.1-12.5 microgram + 5 microgram conjugated to 3.3-8.3 microgram + 5 microgram conjugated to 5.6-10 microgram	injection, powder, for solution	Authorised	Glaxosmithkline Pte LTD
NimenrixCombination	Canada	5 MCG / 0.5 ML + 5 MCG / 0.5 ML + 5 MCG / 0.5 ML + 5 MCG / 0.5 ML + 44 MCG / 0.5 ML	Kit, Powder For Solution	Marketed	Pfizer Canada Ulc

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.